Standardization for Statin-InducedMyotoxicity according to A Alfirevic et al.

Subtype 0: Mild elevation of creatine kinase (CK) levels (< 4 times the upper limit of normal, ULN) without clinical muscle symptoms.
Subtype 1: Presence of muscle symptoms (e.g., myalgia, weakness) without elevation of CK levels.
Subtype 2: Muscle symptoms accompanied by mild CK elevation (< 4 times ULN).
Subtype 3: Moderate CK elevation (> 4 times ULN and < 10 times ULN), with or without muscle symptoms.
Subtype 4: Significant CK elevation (> 10 times ULN and < 50 times ULN) with muscle symptoms.
Subtype 5: Severe CK elevation (> 10 times ULN with evidence of renal failure and muscle symptoms, or > 50 times ULN).